Perioperative management of Takotsubo cardiomyopathy: an overview

Marta Pillitteri1, Etrusca Brogi2, Chiara Piagnani1

  • 1Department of Anaesthesia and Intensive Care, University of Pisa, Pisa, Italy.

Insights

Takotsubo cardiomyopathy, a stress-induced heart condition, often occurs during surgery. Anesthesiologists must understand its management in perioperative settings.

Area of Science:

  • Cardiology
  • Anesthesiology
  • Cardiovascular Research

Background:

  • Takotsubo cardiomyopathy (TTC) presents with left ventricular apical ballooning and basal hyperkinesia, resembling Japanese polyp vessels.
  • The condition is linked to heightened beta-adrenergic receptor sensitivity in apical myocardium, increasing susceptibility to catecholamine fluctuations.
  • TTC is frequently triggered by severe emotional or physical stress, with a rising incidence in the perioperative period.

Purpose of the Study:

  • To provide a comprehensive overview of Takotsubo syndrome.
  • To discuss the perioperative management strategies for patients with Takotsubo cardiomyopathy.
  • To highlight the role of anesthesiologists in managing stress cardiomyopathy during and before surgical procedures.

Main Methods:

  • Literature review on Takotsubo cardiomyopathy pathophysiology and clinical presentation.
  • Analysis of current treatment approaches and guidelines (or lack thereof) for TTC.
  • Discussion of anesthesiologic considerations and management strategies in surgical settings.

Main Results:

  • Takotsubo cardiomyopathy is increasingly diagnosed perioperatively, posing challenges for anesthetic management.
  • Surgery, anesthesia induction, and critical illness are identified as potential triggers for stress cardiomyopathy.
  • Current treatment relies heavily on clinical experience due to a lack of universally accepted guidelines.

Conclusions:

  • Anesthesiologists play a crucial role in managing patients with new-onset or pre-existing Takotsubo cardiomyopathy undergoing surgery.
  • Understanding the triggers and pathophysiology of TTC is essential for safe perioperative care.
  • Further research and standardized guidelines are needed for optimal Takotsubo cardiomyopathy management in surgical patients.

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
564
Increased pulse rate01:17

Increased pulse rate

Tachycardia is a condition marked by an abnormally fast or irregular heart rate, surpassing the typical resting rate. In adults, tachycardia is characterized by a pulse rate ranging from 100 to 180 beats per minute. The increased heart rate can result in inadequate blood flow to various body parts, ultimately diminishing the oxygen supply to organs and tissues.
Many factors can elevate the risk of developing tachycardia. These include advanced age, a family history of arrhythmias, and an...
651
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
419